Magnesium Aspartate: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: April 17, 2026🚩 Report this page

Magnesium Aspartate

Magnesium

GB MHRA

Drug class: Magnesium
Availability: See label
Markets covered: 1
Products on record: 2

Overview

Magnesium Aspartate is an active pharmaceutical ingredient in the Magnesium group (A12CC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	2	April 17, 2026

GBUnited Kingdom· MHRA

2 products

Uses

GBOfficial regulatory label· revised April 17, 2026[1]

Magnesium Aspartate Kora Healthcare is indicated for the treatment and prevention of magnesium deficiency in adults and children aged 10 years and above.

How to take

Sources & citations

[1]MHRA (UK) · PL399720028 · revised April 17, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised April 17, 2026[1]

The assessment of side effects is based on the following frequencies:
Very common (≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1,000 to <1/100); Rare (≥1/10,000 to <1/1,000); Very rare (<1/10,000); Not known (frequency cannot be estimated from the available data). MedDRA System Organ Class Frequency Undesirable Effects Gastrointestinal disorders Uncommon Soft stools or diarrhoea following high dosage General disorders and administration site conditions Very rare fatigue if used long-term At high dosage, diarrhoea or gastrointestinal irritation may occur.
If it occurs, the daily dose should be reduced and gradually increase later if needed. Signs of tiredness may occur with high-dose, prolonged use of Magnesium Aspartate Kora Healthcare. This may be an indication that an elevated magnesium level has been achieved.
In this case, the dose should be reduced, or the medication should be temporarily discontinued. Reporting suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised April 17, 2026[1]

In the case of confirmed magnesium deficiency, concomitant hypocalcaemia and hypokalaemia should be suspected and corrected if confirmed since magnesium deficiency is frequently secondary to those conditions. If an undesirable effect occurs, such as diarrhoea, the therapy should be temporarily interrupted and can be restarted after improvement and /or elimination of the symptoms with a reduced dosage.
The bioavailability of magnesium preparations can vary; therefore, caution should be exercised when switching between magnesium preparations to ensure tolerability and equivalent therapeutic effect.
Excipients:
Sorbitol is a source of fructose. The additive effect of concomitantly administered products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account. The content of sorbitol in medicinal products for oral use may affect the bioavailability of other medicinal products for oral use administered concomitantly.
Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product. Sorbitol may cause gastrointestinal discomfort and mild laxative effect. This medicinal product contains 435 mg sodium per dose, equivalent to 7 % of the WHO recommended maximum daily intake for sodium.
The maximum daily dose of this product is equivalent to 14 % of the WHO recommended maximum daily intake for sodium. Magnesium Aspartate Kora Healthcare is considered high in sodium. This should be particularly taken into account for those on a low salt diet.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drugs in the same class

Sources & citations